Latest News and Press Releases

First investigational trial of a drug-biologic bone graft for spine fusionPhase 2 trial in the U.S. compares Fibrin-PTH (KUR-113) with local autograftPrimary endpoint is radiographic interbody fusion...

  Financial and Operational Highlights CHF 16.0 million cash & cash equivalents, trade and other receivables as at June 30, 2020Revenues increased to CHF 1.3 million driven by strong MagnetOs...

Grant of European patent entitled ‘Osteoinductive composites’Notice of allowance of Japanese patent from the same patent familyFurther strengthens Kuros’s position as a leader in the field of...

Financial highlights CHF 21.9 million cash & cash equivalents, trade and other receivables as at December 31, 2019Revenues increased to CHF 2.6 million Net operating costs decreased to CHF 13.5...

Grant of US patent covering the use of PTH containing matrices for spinal fusionGrant of US patent covering osteoinductive materials made by certain methodsFurther strengthens Kuros’s position as a...

Head-head study of spinal fusion versus the ‘best-in-class’ alternatives within categoryAccepted for publication in Clinical Spine Surgery – a surgeon focused journalPresented by leading academic...

SCHLIEREN (ZURICH), Switzerland, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Kuros Biosciences, (SWX: KURN) a full-fledged orthobiologics company with scientific, clinical, and commercial excellence in bone...

Kuros to fully launch MagnetOs™ at the North American Spine Society 34th Annual Meeting in Chicago, USA, September 25-28, building on the momentum gained during the initial phased launch. Kuros...

Kuros to conduct Phase 2a trial in spinal fusion, comparing Fibrin-PTH to autograftPrimary endpoint is radiographic interbody fusion at 12 months SCHLIEREN (ZURICH), Switzerland, Sept. 03, 2019 ...

Financial highlights CHF 13.4 million cash and cash equivalents (including trade and other receivables) at June 30, 2019Product sales were CHF 0.9 million in the first half of 2019, a substantial...